These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29290374)

  • 1. Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration.
    Kidd JM; Avery LM; Asempa TE; Nicolau DP; Kuti JL
    Clin Ther; 2018 Feb; 40(2):261-269. PubMed ID: 29290374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
    Avery LM; Chen IH; Reyes S; Nicolau DP; Kuti JL
    Clin Ther; 2019 Oct; 41(10):2162-2170. PubMed ID: 31506218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices.
    Chen IH; Martin EK; Nicolau DP; Kuti JL
    Clin Ther; 2020 Apr; 42(4):606-613. PubMed ID: 32139176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
    Shoulders BR; Casapao AM; Venugopalan V
    Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
    Ruiz VH; Shen Y; Abouelhassan Y; Fouad A; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2024 Jan; 81(1):e21-e29. PubMed ID: 37740370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the Meropenem Component of Meropenem-Vaborbactam in the Treatment of KPC-Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient.
    Hanretty AM; Kaur I; Evangelista AT; Moore WS; Enache A; Chopra A; Cies JJ
    Pharmacotherapy; 2018 Dec; 38(12):e87-e91. PubMed ID: 30300440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and Simulation.
    Zhuang L; Yu Y; Wei X; Florian J; Jang SH; Reynolds KS; Wang Y
    J Clin Pharmacol; 2020 Aug; 60(8):1011-1021. PubMed ID: 32149406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
    Albin OR; Patel TS; Kaye KS
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
    Wu G; Cheon E
    Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
    Monogue ML; Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jan; 75(1):e36-e44. PubMed ID: 29273611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an
    Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
    Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
    Lee YR; Baker NT
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection.
    Burgos RM; Biagi MJ; Rodvold KA; Danziger LH
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1007-1021. PubMed ID: 30106599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination.
    Cho JC; Zmarlicka MT; Shaeer KM; Pardo J
    Ann Pharmacother; 2018 Aug; 52(8):769-779. PubMed ID: 29514462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
    Asempa TE; Avery LM; Kidd JM; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jul; 75(14):1048-1056. PubMed ID: 29895521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.